Targeted Drug EGFR RTK Inhibitors for NSCLC Market Report

China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • POSTDATE：Aug 22, 2022
  • PAGES：225
  • REPORT CODE：GMM1080736
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the China Targeted Drug EGFR RTK Inhibitors for NSCLC market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Targeted Drug EGFR RTK Inhibitors for NSCLC market. Detailed analysis of key players, along with key growth strategies adopted by Targeted Drug EGFR RTK Inhibitors for NSCLC industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Fresenius Kabi India

    • Beacon Pharmaceuticals

    • Qilu Pharmaceutical

    • Mylan

    • Genvio Pharma Limited

    • RPG Life Sciences

    • Cipla Pharma

    • Hetero Drugs

    • Intas Pharmaceuticals

    • Zydus Cadila

    • AstraZeneca

    • Beta Pharma

    • Drug International Limted

    • Pfizer

    • Alkem Laboratories

    • Genentech (Roche Group)

    • Natco Pharma

    • Everest Pharmaceuticals

    • Glenmark Pharmaceuticals

    • OSI Pharmaceuticals

    • Boehringer Ingelheim

    • Dr Reddy's Laboratories

    • Incepta Pharmaceuticals Limited

    • ARIAD Pharmaceuticals (Takeda)

    • Teva

    By Type:

    • Icotinib

    • Gefitinib

    • Erlotinib

    • Afatinib

    • Osimertinib

    • Brigatinib

    • Other

    By End-User:

    • Squamous Cell Carcinoma of NSCLC

    • Adenocarcinoma of NSCLC

    • Large Cell Carcinoma of NSCLC

    By Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Targeted Drug EGFR RTK Inhibitors for NSCLC Market

    • 1.3 Market Segment by Type

    • 1.3.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Icotinib from 2016 to 2027

    • 1.3.2 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Gefitinib from 2016 to 2027

    • 1.3.3 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Erlotinib from 2016 to 2027

    • 1.3.4 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Afatinib from 2016 to 2027

    • 1.3.5 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Osimertinib from 2016 to 2027

    • 1.3.6 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Brigatinib from 2016 to 2027

    • 1.3.7 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Other from 2016 to 2027

    • 1.4 Market Segment by Application

    • 1.4.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Squamous Cell Carcinoma of NSCLC from 2016 to 2027

    • 1.4.2 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Adenocarcinoma of NSCLC from 2016 to 2027

    • 1.4.3 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Large Cell Carcinoma of NSCLC from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.5 Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.6 Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.7 Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Targeted Drug EGFR RTK Inhibitors for NSCLC Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Targeted Drug EGFR RTK Inhibitors for NSCLC by Major Types

    • 3.4.1 Market Size and Growth Rate of Icotinib

    • 3.4.2 Market Size and Growth Rate of Gefitinib

    • 3.4.3 Market Size and Growth Rate of Erlotinib

    • 3.4.4 Market Size and Growth Rate of Afatinib

    • 3.4.5 Market Size and Growth Rate of Osimertinib

    • 3.4.6 Market Size and Growth Rate of Brigatinib

    • 3.4.7 Market Size and Growth Rate of Other

    4 Segmentation of Targeted Drug EGFR RTK Inhibitors for NSCLC Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Targeted Drug EGFR RTK Inhibitors for NSCLC by Major End-Users

    • 4.4.1 Market Size and Growth Rate of Targeted Drug EGFR RTK Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC

    • 4.4.2 Market Size and Growth Rate of Targeted Drug EGFR RTK Inhibitors for NSCLC in Adenocarcinoma of NSCLC

    • 4.4.3 Market Size and Growth Rate of Targeted Drug EGFR RTK Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC

    5 Market Analysis by Regions

    • 5.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Production Analysis by Regions

    • 5.2 China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on China Economy

    6 North China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis

    • 6.1 North China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major Types

    • 6.2 North China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major End-Users

    7 Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis

    • 7.1 Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major Types

    • 7.2 Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major End-Users

    8 South China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis

    • 8.1 South China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major Types

    • 8.2 South China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major End-Users

    9 East China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis

    • 9.1 East China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major Types

    • 9.2 East China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major End-Users

    10 Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis

    • 10.1 Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major Types

    • 10.2 Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major End-Users

    11 Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis

    • 11.1 Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major Types

    • 11.2 Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major End-Users

    12 Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis

    • 12.1 Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major Types

    • 12.2 Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Landscape Analysis by Major End-Users

    13 Major Players Profiles

    • 13.1 Fresenius Kabi India

      • 13.1.1 Fresenius Kabi India Company Profile and Recent Development

      • 13.1.2 Market Performance

      • 13.1.3 Product and Service Introduction

    • 13.2 Beacon Pharmaceuticals

      • 13.2.1 Beacon Pharmaceuticals Company Profile and Recent Development

      • 13.2.2 Market Performance

      • 13.2.3 Product and Service Introduction

    • 13.3 Qilu Pharmaceutical

      • 13.3.1 Qilu Pharmaceutical Company Profile and Recent Development

      • 13.3.2 Market Performance

      • 13.3.3 Product and Service Introduction

    • 13.4 Mylan

      • 13.4.1 Mylan Company Profile and Recent Development

      • 13.4.2 Market Performance

      • 13.4.3 Product and Service Introduction

    • 13.5 Genvio Pharma Limited

      • 13.5.1 Genvio Pharma Limited Company Profile and Recent Development

      • 13.5.2 Market Performance

      • 13.5.3 Product and Service Introduction

    • 13.6 RPG Life Sciences

      • 13.6.1 RPG Life Sciences Company Profile and Recent Development

      • 13.6.2 Market Performance

      • 13.6.3 Product and Service Introduction

    • 13.7 Cipla Pharma

      • 13.7.1 Cipla Pharma Company Profile and Recent Development

      • 13.7.2 Market Performance

      • 13.7.3 Product and Service Introduction

    • 13.8 Hetero Drugs

      • 13.8.1 Hetero Drugs Company Profile and Recent Development

      • 13.8.2 Market Performance

      • 13.8.3 Product and Service Introduction

    • 13.9 Intas Pharmaceuticals

      • 13.9.1 Intas Pharmaceuticals Company Profile and Recent Development

      • 13.9.2 Market Performance

      • 13.9.3 Product and Service Introduction

    • 13.10 Zydus Cadila

      • 13.10.1 Zydus Cadila Company Profile and Recent Development

      • 13.10.2 Market Performance

      • 13.10.3 Product and Service Introduction

    • 13.11 AstraZeneca

      • 13.11.1 AstraZeneca Company Profile and Recent Development

      • 13.11.2 Market Performance

      • 13.11.3 Product and Service Introduction

    • 13.12 Beta Pharma

      • 13.12.1 Beta Pharma Company Profile and Recent Development

      • 13.12.2 Market Performance

      • 13.12.3 Product and Service Introduction

    • 13.13 Drug International Limted

      • 13.13.1 Drug International Limted Company Profile and Recent Development

      • 13.13.2 Market Performance

      • 13.13.3 Product and Service Introduction

    • 13.14 Pfizer

      • 13.14.1 Pfizer Company Profile and Recent Development

      • 13.14.2 Market Performance

      • 13.14.3 Product and Service Introduction

    • 13.15 Alkem Laboratories

      • 13.15.1 Alkem Laboratories Company Profile and Recent Development

      • 13.15.2 Market Performance

      • 13.15.3 Product and Service Introduction

    • 13.16 Genentech (Roche Group)

      • 13.16.1 Genentech (Roche Group) Company Profile and Recent Development

      • 13.16.2 Market Performance

      • 13.16.3 Product and Service Introduction

    • 13.17 Natco Pharma

      • 13.17.1 Natco Pharma Company Profile and Recent Development

      • 13.17.2 Market Performance

      • 13.17.3 Product and Service Introduction

    • 13.18 Everest Pharmaceuticals

      • 13.18.1 Everest Pharmaceuticals Company Profile and Recent Development

      • 13.18.2 Market Performance

      • 13.18.3 Product and Service Introduction

    • 13.19 Glenmark Pharmaceuticals

      • 13.19.1 Glenmark Pharmaceuticals Company Profile and Recent Development

      • 13.19.2 Market Performance

      • 13.19.3 Product and Service Introduction

    • 13.20 OSI Pharmaceuticals

      • 13.20.1 OSI Pharmaceuticals Company Profile and Recent Development

      • 13.20.2 Market Performance

      • 13.20.3 Product and Service Introduction

    • 13.21 Boehringer Ingelheim

      • 13.21.1 Boehringer Ingelheim Company Profile and Recent Development

      • 13.21.2 Market Performance

      • 13.21.3 Product and Service Introduction

    • 13.22 Dr Reddy's Laboratories

      • 13.22.1 Dr Reddy's Laboratories Company Profile and Recent Development

      • 13.22.2 Market Performance

      • 13.22.3 Product and Service Introduction

    • 13.23 Incepta Pharmaceuticals Limited

      • 13.23.1 Incepta Pharmaceuticals Limited Company Profile and Recent Development

      • 13.23.2 Market Performance

      • 13.23.3 Product and Service Introduction

    • 13.24 ARIAD Pharmaceuticals (Takeda)

      • 13.24.1 ARIAD Pharmaceuticals (Takeda) Company Profile and Recent Development

      • 13.24.2 Market Performance

      • 13.24.3 Product and Service Introduction

    • 13.25 Teva

      • 13.25.1 Teva Company Profile and Recent Development

      • 13.25.2 Market Performance

      • 13.25.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Icotinib from 2016 to 2027

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Gefitinib from 2016 to 2027

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Erlotinib from 2016 to 2027

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Afatinib from 2016 to 2027

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Osimertinib from 2016 to 2027

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Brigatinib from 2016 to 2027

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Other from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2021

    • Figure Market Share by Type in 2027

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Squamous Cell Carcinoma of NSCLC from 2016 to 2027

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Adenocarcinoma of NSCLC from 2016 to 2027

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Growth Rate of Large Cell Carcinoma of NSCLC from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2021

    • Figure Market Share by End-User in 2027

    • Figure North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Targeted Drug EGFR RTK Inhibitors for NSCLC Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2020

    • Figure Market Share of TOP 5 Players in 2021

    • Figure Market Share of TOP 6 Players from 2016 to 2021

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Map of China

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Targeted Drug EGFR RTK Inhibitors for NSCLC

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Targeted Drug EGFR RTK Inhibitors for NSCLC by Different Types from 2016 to 2027

    • Table Consumption Share of Targeted Drug EGFR RTK Inhibitors for NSCLC by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of Icotinib

    • Figure Market Size and Growth Rate of Gefitinib

    • Figure Market Size and Growth Rate of Erlotinib

    • Figure Market Size and Growth Rate of Afatinib

    • Figure Market Size and Growth Rate of Osimertinib

    • Figure Market Size and Growth Rate of Brigatinib

    • Figure Market Size and Growth Rate of Other

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Targeted Drug EGFR RTK Inhibitors for NSCLC by Different End-Users from 2016 to 2027

    • Table Consumption Share of Targeted Drug EGFR RTK Inhibitors for NSCLC by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Squamous Cell Carcinoma of NSCLC

    • Figure Market Size and Growth Rate of Adenocarcinoma of NSCLC

    • Figure Market Size and Growth Rate of Large Cell Carcinoma of NSCLC

    • Table China Targeted Drug EGFR RTK Inhibitors for NSCLC Production by Regions

    • Table China Targeted Drug EGFR RTK Inhibitors for NSCLC Production Share by Regions

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Production Share by Regions in 2016

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Production Share by Regions in 2021

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Production Share by Regions in 2027

    • Table China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Regions

    • Table China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Regions

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Regions in 2016

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Regions in 2021

    • Figure China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Regions in 2027

    • Table North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure North China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure Central China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure South China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure East China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure Northeast China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure Southwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by Types from 2016 to 2027

    • Table Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types from 2016 to 2027

    • Figure Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2016

    • Figure Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2021

    • Figure Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by Types in 2027

    • Table Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption by End-Users from 2016 to 2027

    • Table Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users from 2016 to 2027

    • Figure Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2016

    • Figure Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2021

    • Figure Northwest China Targeted Drug EGFR RTK Inhibitors for NSCLC Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Fresenius Kabi India

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Fresenius Kabi India

    • Figure Sales and Growth Rate Analysis of Fresenius Kabi India

    • Figure Revenue and Market Share Analysis of Fresenius Kabi India

    • Table Product and Service Introduction of Fresenius Kabi India

    • Table Company Profile and Development Status of Beacon Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Beacon Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Beacon Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Beacon Pharmaceuticals

    • Table Product and Service Introduction of Beacon Pharmaceuticals

    • Table Company Profile and Development Status of Qilu Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Qilu Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Qilu Pharmaceutical

    • Figure Revenue and Market Share Analysis of Qilu Pharmaceutical

    • Table Product and Service Introduction of Qilu Pharmaceutical

    • Table Company Profile and Development Status of Mylan

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Mylan

    • Figure Sales and Growth Rate Analysis of Mylan

    • Figure Revenue and Market Share Analysis of Mylan

    • Table Product and Service Introduction of Mylan

    • Table Company Profile and Development Status of Genvio Pharma Limited

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Genvio Pharma Limited

    • Figure Sales and Growth Rate Analysis of Genvio Pharma Limited

    • Figure Revenue and Market Share Analysis of Genvio Pharma Limited

    • Table Product and Service Introduction of Genvio Pharma Limited

    • Table Company Profile and Development Status of RPG Life Sciences

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of RPG Life Sciences

    • Figure Sales and Growth Rate Analysis of RPG Life Sciences

    • Figure Revenue and Market Share Analysis of RPG Life Sciences

    • Table Product and Service Introduction of RPG Life Sciences

    • Table Company Profile and Development Status of Cipla Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Cipla Pharma

    • Figure Sales and Growth Rate Analysis of Cipla Pharma

    • Figure Revenue and Market Share Analysis of Cipla Pharma

    • Table Product and Service Introduction of Cipla Pharma

    • Table Company Profile and Development Status of Hetero Drugs

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Hetero Drugs

    • Figure Sales and Growth Rate Analysis of Hetero Drugs

    • Figure Revenue and Market Share Analysis of Hetero Drugs

    • Table Product and Service Introduction of Hetero Drugs

    • Table Company Profile and Development Status of Intas Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Intas Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Intas Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Intas Pharmaceuticals

    • Table Product and Service Introduction of Intas Pharmaceuticals

    • Table Company Profile and Development Status of Zydus Cadila

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Zydus Cadila

    • Figure Sales and Growth Rate Analysis of Zydus Cadila

    • Figure Revenue and Market Share Analysis of Zydus Cadila

    • Table Product and Service Introduction of Zydus Cadila

    • Table Company Profile and Development Status of AstraZeneca

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca

    • Figure Sales and Growth Rate Analysis of AstraZeneca

    • Figure Revenue and Market Share Analysis of AstraZeneca

    • Table Product and Service Introduction of AstraZeneca

    • Table Company Profile and Development Status of Beta Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Beta Pharma

    • Figure Sales and Growth Rate Analysis of Beta Pharma

    • Figure Revenue and Market Share Analysis of Beta Pharma

    • Table Product and Service Introduction of Beta Pharma

    • Table Company Profile and Development Status of Drug International Limted

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Drug International Limted

    • Figure Sales and Growth Rate Analysis of Drug International Limted

    • Figure Revenue and Market Share Analysis of Drug International Limted

    • Table Product and Service Introduction of Drug International Limted

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Alkem Laboratories

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Alkem Laboratories

    • Figure Sales and Growth Rate Analysis of Alkem Laboratories

    • Figure Revenue and Market Share Analysis of Alkem Laboratories

    • Table Product and Service Introduction of Alkem Laboratories

    • Table Company Profile and Development Status of Genentech (Roche Group)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Genentech (Roche Group)

    • Figure Sales and Growth Rate Analysis of Genentech (Roche Group)

    • Figure Revenue and Market Share Analysis of Genentech (Roche Group)

    • Table Product and Service Introduction of Genentech (Roche Group)

    • Table Company Profile and Development Status of Natco Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Natco Pharma

    • Figure Sales and Growth Rate Analysis of Natco Pharma

    • Figure Revenue and Market Share Analysis of Natco Pharma

    • Table Product and Service Introduction of Natco Pharma

    • Table Company Profile and Development Status of Everest Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Everest Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Everest Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Everest Pharmaceuticals

    • Table Product and Service Introduction of Everest Pharmaceuticals

    • Table Company Profile and Development Status of Glenmark Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Glenmark Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Glenmark Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Glenmark Pharmaceuticals

    • Table Product and Service Introduction of Glenmark Pharmaceuticals

    • Table Company Profile and Development Status of OSI Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of OSI Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of OSI Pharmaceuticals

    • Figure Revenue and Market Share Analysis of OSI Pharmaceuticals

    • Table Product and Service Introduction of OSI Pharmaceuticals

    • Table Company Profile and Development Status of Boehringer Ingelheim

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Boehringer Ingelheim

    • Figure Sales and Growth Rate Analysis of Boehringer Ingelheim

    • Figure Revenue and Market Share Analysis of Boehringer Ingelheim

    • Table Product and Service Introduction of Boehringer Ingelheim

    • Table Company Profile and Development Status of Dr Reddy's Laboratories

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dr Reddy's Laboratories

    • Figure Sales and Growth Rate Analysis of Dr Reddy's Laboratories

    • Figure Revenue and Market Share Analysis of Dr Reddy's Laboratories

    • Table Product and Service Introduction of Dr Reddy's Laboratories

    • Table Company Profile and Development Status of Incepta Pharmaceuticals Limited

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Incepta Pharmaceuticals Limited

    • Figure Sales and Growth Rate Analysis of Incepta Pharmaceuticals Limited

    • Figure Revenue and Market Share Analysis of Incepta Pharmaceuticals Limited

    • Table Product and Service Introduction of Incepta Pharmaceuticals Limited

    • Table Company Profile and Development Status of ARIAD Pharmaceuticals (Takeda)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of ARIAD Pharmaceuticals (Takeda)

    • Figure Sales and Growth Rate Analysis of ARIAD Pharmaceuticals (Takeda)

    • Figure Revenue and Market Share Analysis of ARIAD Pharmaceuticals (Takeda)

    • Table Product and Service Introduction of ARIAD Pharmaceuticals (Takeda)

    • Table Company Profile and Development Status of Teva

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Teva

    • Figure Sales and Growth Rate Analysis of Teva

    • Figure Revenue and Market Share Analysis of Teva

    • Table Product and Service Introduction of Teva


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US